Published Paper Details:

Abstract: Anaplastic astrocytoma (AA) is a rare, aggressive Grade III primary brain tumor arising from astrocytes. It predominantly affects adults aged 30-50 years and is characterized by increased cellular atypia, mitotic activity, and a high risk of progression to glioblastoma. Genetic alterations, including TP53 mutations, ATRX deletions, and IDH1/IDH2 mutations, significantly influence prognosis. Clinically, patients present with progressive neurological deficits, seizures, and cognitive decline. Magnetic resonance imaging (MRI) with contrast serves as the primary diagnostic tool, revealing non-enhancing lesions with variable edema. Histopathological analysis and genetic profiling confirm the diagnosis and guide treatment. Standard management includes maximal surgical resection, followed by radiation therapy and temozolomide-based chemotherapy. Molecular markers and extent of resection impact survival, with IDH-mutant tumors having a better prognosis. Despite advancements, AA remains challenging to treat, necessitating further research into targeted therapies and immunotherapy to improve outcomes.